QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:MYGN

Myriad Genetics - MYGN Stock Forecast, Price & News

$19.72
+0.46 (+2.39%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$19.11
$19.81
50-Day Range
$14.51
$21.41
52-Week Range
$13.92
$28.18
Volume
666,567 shs
Average Volume
588,644 shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.40

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
28.8% Upside
$25.40 Price Target
Short Interest
Healthy
3.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.62mentions of Myriad Genetics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$503,382 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.80) to ($0.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

253rd out of 1,055 stocks

Diagnostic Substances Industry

5th out of 17 stocks


MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

3 Small Caps That Have Big Upside (MYGN)
If market sentiment stays bullish, small caps with depressed shares prices and valuation could turn into big-time outperformers.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Why Shares of Myriad Genetics Dropped 24% This Week
Myriad Genetics: All You Need To Know About Q3 Earnings
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
11/02/2021
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,400
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$25.40
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+28.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-27,200,000.00
Pretax Margin
-19.96%

Debt

Sales & Book Value

Annual Sales
$690.60 million
Cash Flow
$0.45 per share
Book Value
$12.12 per share

Miscellaneous

Free Float
79,575,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.75

Social Links


Key Executives

  • Paul J. Diaz
    President, Chief Executive Officer & Director
  • Nicole LambertNicole Lambert
    Chief Operating Officer
  • R. Bryan Riggsbee
    Chief Financial Officer, Treasurer & Executive VP
  • Dale Muzzey
    Chief Scientific Officer
  • Kevin R. Haas
    Chief Technology Officer













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2023?

4 analysts have issued 12 month price objectives for Myriad Genetics' stock. Their MYGN share price forecasts range from $22.00 to $32.00. On average, they expect the company's share price to reach $25.40 in the next year. This suggests a possible upside of 28.8% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2023?

Myriad Genetics' stock was trading at $14.51 at the beginning of 2023. Since then, MYGN stock has increased by 35.9% and is now trading at $19.72.
View the best growth stocks for 2023 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The company had revenue of $167.30 million for the quarter, compared to analysts' expectations of $164.35 million. Myriad Genetics had a negative net margin of 11.69% and a negative trailing twelve-month return on equity of 4.86%. During the same period in the prior year, the company earned ($0.19) EPS.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of -$0.35--$0.30 for the period, compared to the consensus earnings per share estimate of -$0.06. The company issued revenue guidance of $668.00 million-$672.00 million, compared to the consensus revenue estimate of $692.18 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (0.20%), Assenagon Asset Management S.A. (0.11%), Comerica Bank (0.11%), Fifth Third Bancorp (0.08%), Natixis Advisors L.P. (0.07%) and State of Alaska Department of Revenue (0.07%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends
.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $19.72.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.60 billion and generates $690.60 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,400 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 1/31/2023 by MarketBeat.com Staff